Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

A translational platform for brain-computer interfaces and adaptive neuromodulation: Technical characterization, long-term validation, and implementation of the CorTec brain interchange-BCI2000 ecosystem
Lampert, Frederik , Baker, Matthew R , Engelhardt, William , Gkogkidis, C Alexis , Ayyoubi, Amir Hossein , Fazli Besheli, Behrang , Boom, Max van den , Kellar, Douglas J , Kim, Inyong , Staff, Nathan P , Schalk, Gerwin , Ince, Nuri Firat

Mayo Clinic

Journal of Neural Engineering | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1088/1741-2552/aec198 | PMID 43019594 Get It

Abstract Objective: Adaptive neuromodulation systems and implantable brain-computer interfaces (BCIs) are promising therapies for neurological and psychiatric disorders. However, their broader translation into research and clinical practice remains limited by technological complexity, restricted access to implantable research platforms, and the lack of standardized, reproducible experimental workflows. We therefore aimed to develop and validate an open, general-purpose translational ecosystem that enables rapid development, evaluation, and dissemination of novel neuromodulation and implantable BCI paradigms.
Approach: The CorTec Brain Interchange (BIC) implantable neural sensing and stimulation device was integrated with the open-source BCI2000 platform to create a modular, extensible neuromodulation ecosystem. We established a standardized battery of quantitative assessments to characterize implantable neuromodulation systems to comprehensively evaluate the CorTec BIC device through benchtop characterization, long-term preclinical in vivo validation, and a human feasibility demonstration using the benchtop BIC system connected to externalized leads.
Results: Comprehensive benchtop characterization of the BIC device independently validated previously reported performance while extending its evaluation through quantification of recording noise, acquisition and stimulation latencies, and validation of impedance measurements. Long-term in vivo validation in five canines, with the longest implantation exceeding three years, demonstrated stable chronic recordings while also capturing progressive deterioration of individual channels through longitudinal changes in signal quality and impedance. The ecosystem enabled active functional decoding more than two years after implantation, closed-loop stimulation using arbitrary spectral biomarkers, capturing brain stimulation evoked potentials, detection of epilepsy-associated biomarkers and observational assessment of their response to stimulation. In addition, we translated an established one-dimensional BCI cursor-control paradigm to the BIC benchtop system, demonstrating ecosystem portability and feasibility with a human participant. Finally, we share surgical protocols, imaging and analysis pipelines, datasets, and software to facilitate reproducible neuromodulation research.
Significance: We present a versatile, open-source translational ecosystem that supports a wide range of neuromodulation and implantable BCI applications with minimal modification. By combining comprehensive hardware characterization with standardized software tools and experimental workflows, this work provides a practical reference for researchers adopting the BIC platform while establishing a broadly applicable framework for systematic characterization of implantable neuromodulation systems. The ecosystem lowers technical barriers to implantable neurotechnology research, promotes reproducibility, and provides a foundation for accelerating the development and clinical translation of next-generation adaptive neuromodulation and implantable BCI therapies for patients with neurological and psychiatric disorders.
Long-term economic benefits of early cancer detection through enhanced multimodal screening: a modeling study of whole-body MRI and liquid biopsy
Sato, Ryoko , McVeigh, Kim H, Bolan, Candice, Brar, Pamila, Sazama, Naomi, Karow, David

Mayo Clinic

Journal of Comparative Effectiveness Research | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.57264/cer-2026-0099 | PMID 43012102 Get It

Aim: Cancer poses a substantial health and economic burden in the US Although early detection is associated with improved outcomes and lower treatment costs, many cancers are still diagnosed at advanced stages. Enhanced multimodal screening combining whole-body magnetic resonance imaging (WB MRI) and blood-based multicancer early detection (MCED) may shift diagnoses earlier, but its long-term economic impact remains uncertain. Materials & methods: We developed an economic model to estimate expected cancer-related costs under two scenarios: status quo with conventional screening and enhanced multimodal screening incorporating WB MRI and MCED. The analysis included common cancers with an annual incidence of ≥10,000 new cases in the US in 2025. Expected cancer management costs were estimated using incidence-based 5-year stage-specific medical costs. Productivity losses were estimated using a simplified human capital approach, applying published stage-specific work-loss durations to sex-specific annual earnings. Under the intervention arm, conservative, moderate and maximum cancer stage-shift assumptions were evaluated. These scenarios reflected increasing degrees of earlier cancer detection, with a greater proportion of cancers assumed to be diagnosed at earlier stages rather than at advanced stages. Total expected cancer-related costs per person were derived by combining direct medical costs and productivity losses, weighted by cancer risk and stage distribution. Results: Under the status quo, expected cancer-related costs were estimated at $74,431 for men and $78,818 for women. With enhanced multimodal screening under the moderate stage-shift assumption, costs, including screening and false positive workup, declined to about $66,000 and $69,500, respectively, representing approximately 12% reduction. Under the conservative stage-shift assumption, total costs were similar to those under the status quo, whereas under the maximum stage-shift assumption, cost reductions ranged from 24.0% to 24.3% for men and from 24.7% to 25.0% for women. Conclusion: Enhanced multimodal screening may reduce the economic burden of cancer by shifting diagnosis toward earlier stages, although the magnitude of benefit depends substantially on the extent to which cancers are detected at earlier stages in practice. These findings highlight the potential long-term economic value of earlier cancer detection while underscoring the need for prospective evidence on the real-world performance of WB-MRI and MCED screening strategies. Because long-term real-world data for population-level WB-MRI and MCED screening remain limited, these findings should be interpreted as estimates of potential economic impact rather than projections of a specific screening program.
Targeting NF-κB prevents Schwann cell reprogramming and plexiform neurofibroma initiation in mouse model of Nf1
Ravindran, Ramya , Youn, Eui-Kyung, Kedei, Noémi , Choi, Kwangmin , Volz, Avery, Dombi, Eva , Pundavela, Jay , Kim, MiOk, Spinner, Robert J. , Szabo, Sara , Largaespada, David A. , Shern, Jack F. , Ratner, Nancy

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.764357 Get It

Plexiform neurofibromas arise in approximately half of all individuals with Neurofibromatosis Type I (NF1). Genetic lesions apart from NF1 pathogenic variants are not present in NF1 mutant Schwann cells, suggesting that tumorigenesis may instead require cellular rewiring. To identify putatively re-wired tumor cells, we used multiplex imaging and flow cytometry to delineate markers that distinguish tumor Schwann cell from non-tumor Schwann cells. We identified tumor Schwann cells as CD44+;CD49f+ cells that show increased transcription of epithelial to mesenchymal plasticity (EMP)- associated genes. CD44+;CD49f+ expression was induced by treating Nf1-/- Schwann cells with stressors or by direct NF-κB pathway activation via IKK2; treated Schwann cells increased secretion of NF-κB targets and immune cell chemoattractants CCL2 and CCL3. In established tumors, MEK inhibition plus NF-κB blockade diminished tumor cell proliferation, tumor Schwann cells, immune cell populations, tumor cytokines and tumor number. Notably, transient single agent NF-κB pathway blockade was sufficient to significantly delay tumor formation in mice. Thus, Nf1 loss in Schwann cells is followed by NF-κB activation and cellular reprogramming that drives tumor initiation and targeting NF-κB activation can reduce NF1-deficient tumor formation.
An Evidence-Based Approach to Zenker's Diverticulum: From Diagnosis to Tailored Treatment
Kim, Marina

Mayo Clinic

American Journal of Gastroenterology | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004228 | PMID 42847187 Get It

Serial Artificial Intelligence ECG-Derived Atrial Fibrillation Probability and Recurrence Risk After Pulsed Field Ablation
Sardana, Mayank , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Kim, James , Attia, Zachi I , Wood, Julia , Mangold, Kathryn E , Friedman, Paul A , Noseworthy, Peter A , Srivathsan, Komandoor

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circep.126.015183 | PMID 42845233 Get It

BACKGROUND: Pulsed field ablation is now widely used for atrial fibrillation (AF) ablation, but atrial tachyarrhythmia recurrence remains common and postablation risk tools are limited. We assessed whether a validated sinus‑rhythm artificial intelligence— enabled ECG AF probability score, and its early postablation change, predicts recurrence after pulsed field ablation. METHODS: We studied consecutive patients undergoing index pulsed field ablation across 3 Mayo Clinic sites (February 2024–March 2025) with ≥1 sinus‑rhythm ECG within 180 days preprocedure. Baseline artificial intelligence—enabled ECG AF score (range 0–1) was the mean across baseline ECGs. Recovery indices (RI30/60/90), defined as mean postprocedure artificial intelligence—enabled ECG score within days 1–30/60/90 minus baseline, predicted post‑blanking recurrence using corresponding 30‑, 60‑, and 90‑day blanking windows. The primary outcome was time to first documented AF/atrial flutter/atrial tachycardia episode >30 seconds, ascertained via clinic ECGs, ambulatory monitoring, and device interrogations. Cox regression adjusted for prespecified clinical and echocardiographic covariates assessed associations; Harrell C‑statistic quantified discrimination. RESULTS: Among 1052 patients (67±10 years; 33% women), median baseline score was 0.35; 320 (30%) recurred over 188 days. Higher baseline score independently predicted recurrence (hazard ratio per 0.1 increase, 1.08 [95% CI, 1.03–1.14]). Scores rose on day 0 after ablation, then declined over subsequent weeks, with persistently higher, less‑improving trajectories among patients who recurred (time×recurrence interaction P <0.001). Day 0 score was not independently associated with recurrence after adjustment. Attenuated early recovery (higher recovery index) was independently associated with recurrence, most robustly for RI-90 (hazard ratio per 0.1 increase, 1.15 [95% CI, 1.07–1.24]), and improved discrimination beyond baseline and covariates (C‑statistic, 0.63–0.67; ΔC=0.04). Findings were consistent in a historical thermal ablation cohort. CONCLUSIONS: Baseline and early postablation dynamics of a sinus‑rhythm artificial intelligence—enabled ECG AF probability score are associated with pulsed field ablation recurrence and may aid multivariable risk stratification; prospective validation is warranted.
Innovations in Microsurgery: A Qualitative Appraisal of a Novel 3D-Printed Microscope
Zona, Emily E. , Eftekari, Sahand, Wu, Elizabeth P., Quach, Myiah Phuong Kim, Shaffrey, Ellen C , Carbullido, M Kristine, Zeng, Weifeng , Dingle, Aaron M

Mayo Clinic

Journal of Reconstructive Microsurgery | October 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2972-6217 | PMID 42838114 Get It

Background Microsurgery is a critical component of plastic and reconstructive surgery. However, the high cost of training and equipment pose significant barriers, particularly in resource-limited settings. To address this challenge, the Microsurgery and Regenerative Medicine Lab within the Division of Plastic Surgery at the University of Wisconsin developed a low-cost, 3D-printed surgical microscope. This study qualitatively appraised the use of this novel microscope for microsurgery training by surveying surgeons about their experiences using this tool relative to traditional magnification methods. Methods In this prospective, multi-institutional appraisal study, surgical residents, fellows, and attending surgeons with varying microsurgical experience performed a single end-to-end microsurgical anastomosis on chicken thigh femoral arteries using the 3D-printed microscope. Participants then completed a survey assessing ease of use, adequacy for microsurgical training, educational value, and perceived impact on teaching capacity in local and global settings. Results Over 80% of participants reported that performing an end-to-end anastomosis was easier or equivalent using the 3D-printed microscope compared to surgical loupes. All respondents expressed willingness to use the device for microsurgery teaching and practice. Additionally, 91.7% (33/36) believed access to the microscope would enhance microsurgical teaching at their home institutions, and 97.1% (34/35) felt it would improve teaching capacity in globally. Qualitative feedback was overwhelmingly positive, with suggestions primarily related to ergonomics and lighting. Conclusion This study supports that this low-cost, 3D-printed microscope is an effective microsurgical training tool. Ongoing design refinements informed by user feedback may further optimize its role in expanding access to microsurgery education worldwide.
Metabolic reprogramming of pathogenic CD4 + T helper cells attenuates inflammatory bowel disease in mice
Mishra, Shravan K , Abdelrahman, Leena M , Kim Lee, Hyun Se , Valenzuela-Pérez, Lucía , Manna, Dina Faeq , Abram, Tanner J , Ali, Lama Mohamed , Davidson, Heidi M , Hassan, Omar M , Faubion, William A. , Hirsova, Petra , Bamidele, Adebowale O

Mayo Clinic

Science Signaling | October 6, 2026 | Volume: 19 | Issue: 958 | Pages: No page available

10.1126/scisignal.aeb2392 | PMID 42837442 Get It

CD4 + effector T helper 1 (T H 1) cells drive inflammatory bowel disease (IBD). Here, we investigated how integrated signaling, metabolic, and epigenetic programs sustain their pathogenic persistence. We found that enforcing mitochondrial pyruvate metabolism with methyl pyruvate (MePyr) suppressed T H 1 cell effector function and induced the acquisition of a regulatory-like phenotype. MePyr suppressed the activity of glycogen synthase kinase 3β (GSK3β), promoting a metabolic shift from glycolysis toward oxidative phosphorylation (OXPHOS) and limiting the accumulation of intracellular acetyl-CoA. This metabolic reprogramming decreased histone H3 acetylation at genes encoding inflammatory cytokines, thereby decreasing T H 1 cell–associated gene expression. Restoration of inflammatory cytokine production by acetate supplementation or histone deacetylase inhibition established acetyl-CoA–dependent histone acetylation as a mechanistic link between metabolic flux and effector function. Conversely, the cytokine interleukin-21 enhanced T H 1 cell effector activity by promoting a GSK3β-dependent shift from OXPHOS to glycolysis. Single-cell transcriptomic analysis of Crohn’s disease tissue revealed enrichment of glycolytic gene programs in nonregulatory CD4 + T cells. Consistent with these findings, pharmacologic inhibition of GSK3β attenuated disease severity in a T cell–transfer mouse model of colitis. Together, these findings identify a GSK3β-dependent metabolic-epigenetic axis that sustains T H 1 cell pathogenicity and highlight GSK3β as a potential therapeutic target for IBD.
Radiofrequency Catheter Ablation of Atrial Fibrillation in Patients with Anomalous Pulmonary Venous Return: A Multicenter Case Series
Kim, James

Mayo Clinic

No container title available | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.30.26363976 Get It

ABSTRACT Background Atrial fibrillation (AF) has been observed in adults with anomalous pulmonary venous return (APVR), but data on catheter ablation outcomes in this population remain limited to case reports and small series. Methods We retrospectively reviewed 14 adult patients with confirmed APVR who underwent catheter ablation for AF at three tertiary academic centers in the United States between July 2003 and May 2025. Baseline, procedural, electroanatomic mapping, and outcome data were collected. Freedom from atrial arrhythmia recurrence was estimated by Kaplan-Meier analysis. Results Mean age was 56 ± 13 years and 79% were male. Heart failure was present in 64%, and hypertension and coronary artery disease in 43% each. Most had partial APVR (86%), and 57% had prior surgical correction. Radiofrequency ablation was used in all patients, combined with pulsed-field ablation in one. Acute success was achieved in all patients, although areas with residual pulmonary vein or SVC electrical activity were left untreated in 3 (21%). Non-pulmonary-vein electrical activity was more common in patients with prior surgical correction than in those without (43% vs 17%). Median follow-up was 3.4 years (IQR, 2.0-9.6). Freedom from arrhythmia recurrence was 78.6% at 1 year and 53.9% at 5 years. Two patients (14%) required reablation; complications occurred in 3 (21%) without long-term sequelae. Conclusions Catheter ablation was acutely successful in all patients in this largest reported APVR cohort, despite substantial comorbidity burden and anatomic complexity. The arrhythmogenic substrate often extended beyond the anomalous vein, particularly in surgically corrected patients, supporting individualized, substrate-guided ablation in this population. CLINICAL PERSPECTIVE What Is Known Atrial fibrillation has been reported in adults with anomalous pulmonary venous return (APVR), but data on catheter ablation outcomes in this population are limited to case reports and small series. What the Study Adds In the largest reported cohort of patients with APVR undergoing catheter ablation for atrial fibrillation, pulmonary vein isolation achieved acute success in all patients despite substantial comorbidity burden and anatomic complexity. Non-pulmonary-vein sites of electrical activity were more common among patients with prior surgical correction, and postsurgical scar and epicardial venoatrial connections were also arrhythmogenic, indicating that the arrhythmogenic substrate in APVR often extends beyond the anomalous vein itself. These findings support individualized, substrate-guided mapping in patients with APVR, particularly those with a surgical history, and suggest a role for pulsed-field ablation near critical structures such as the phrenic nerve.
NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era
Li, Eric V , Kim, Tae-Hee , Wang, Michael K., O'Byrne, Jamie, Shi, Chloe , Galatowitsch, Peter , Gettman, Matthew

Mayo Clinic

The Prostate | September 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pros.70261 | PMID 42801734 Get It

ABSTRACT Background Prior studies in the pre‐MRI era suggest that patients with NCCN Intermediate and High Risk Grade Group 1 prostate cancer (GG1 PCa) on biopsy have increased risk for adverse oncologic outcomes. However, prostate MRI has altered patient selection for biopsy and improved prostate sampling. Herein, we examined factors associated with adverse pathologic features (APF) at radical prostatectomy (RP) and biochemical recurrence (BCR) among patients with GG1 in the MRI era. Methods A prospectively maintained institutional prostate cancer registry identified patients with GG1 PCa on biopsy who underwent RP from 2000 to 2023, stratified by MRI use. Multivariable logistic regression and Cox regression identified factors associated with APF at RP (GG3‐5, ≥ pT3a, or pN1) and BCR free survival (two consecutive PSA ≥ 0.2 ng/mL), respectively. Results Among patients without MRI ( n = 6732), NCCN risk group was associated with APF, BCR, and distant metastasis. Among 302 patients with GG1 and pre‐operative MRI, NCCN risk group was associated with neither APF nor BCR. Age (OR 1.07, 95% CI 1.01–1.14, p = 0.01), PIRADS ( p = 0.01), and % core positivity (OR 1.02, 95% CI 1.00–1.03, p = 0.04) were associated with APF. Age (HR 1.07, 95% CI 1.01–1.13, p = 0.03), APF (HR 4.36, 95% CI 2.14–8.86, p < 0.001), and positive margins (HR 4.88, 95% CI 2.39–9.98, p < 0.001) were associated with BCR. Conclusions Prior to prostate MRI, NCCN risk groups offered meaningful prognostication among patients with GG1 PCa. However, the utility of NCCN risk groups for GG1 in the MRI era appears limited. Contemporary risk stratification for GG1 should focus on biopsy and MRI characteristics rather than NCCN criteria.
Food Insecurity and Its Association with the Spectrum of Steatotic Liver Disease and Hepatic Fibrosis
Kim, Donghee , Danpanichkul, Pojsakorn , Shenoy, Anoushka , Wijarnpreecha, Karn , Ahmed, Aijaz , Wijarnpreecha, Karn , Kim, Donghee , Danpanichkul, Pojsakorn , Shenoy, Anoushka

Mayo Clinic

Gut and Liver | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.5009/gnl260342 | PMID 42770188 Get It